|
|
Blood, 1 July 2004, Vol. 104, No. 1, pp. 224-226.
Prepublished online as a Blood First Edition Paper on March 18, 2004; DOI 10.1182/blood-2003-07-2461.
Previous Article | Next Article 
Submitted July 21, 2003
Accepted February 18, 2004
Artificial antigen presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes
Liesbeth E Oosten*, Els Blokland, Astrid G van Halteren, Julie Curtsinger, Matthew F Mescher, J H Falkenburg, Tuna Mutis, and Els Goulmy
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
Center of Immunology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
* Corresponding author; email: l.e.m.oosten{at}lumc.nl.
Cytotoxic T lymphocytes (CTLs) specific for hematopoietic restricted minor histocompatibility antigens (mHags) are important reagents for adoptive immunotherapy of relapsed leukemia after allogeneic stem cell transplantation. However, expansion of these CTLs to therapeutic numbers is often hampered by the limited supply of antigen presenting cells (APCs). Therefore, we evaluated whether cell-sized latex beads coated with human leukocyte antigen (HLA) /mHag complexes HLA-A2/HA-1 or HLA-A2/HA-2, and recombinant CD80 and CD54 molecules can replace professional APCs. The artificial antigen presenting constructs (aAPCs) effectively stimulated HA-1 and HA-2 specific CTL clones as shown by ligand-specific expansion, cytokine production and maintenance of cytotoxic activity, without alteration of CTL phenotype. Furthermore, HA-1 specific polyclonal CTL lines were enriched as efficiently by aAPCs as by autologous HA-1 peptide pulsed dendritic cells (DCs). Thus, aAPCs coated with HLA/mHag complexes, CD80 and CD54 may serve as tools for in vitro enrichment of immunotherapeutical mHag-specific CTL lines.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. M. E. Whitelegg, L. E. M. Oosten, S. Jordan, M. Kester, A. G. S. van Halteren, J. A. Madrigal, E. Goulmy, and L. D. Barber
Investigation of Peptide Involvement in T Cell Allorecognition Using Recombinant HLA Class I Multimers
J. Immunol.,
August 1, 2005;
175(3):
1706 - 1714.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Schilbach, G. Kerst, S. Walter, M. Eyrich, D. Wernet, R. Handgretinger, W. Xie, H.-G. Rammensee, I. Muller, H.-J. Buhring, et al.
Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction
Blood,
July 1, 2005;
106(1):
144 - 149.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kami, A. Makimoto, Y. Heike, and Y. Takaue
Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies
Jpn. J. Clin. Oncol.,
December 1, 2004;
34(12):
707 - 716.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |